These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 11921490)
1. Beta-lactam/beta-lactamase inhibitor combinations in empiric management of pediatric infections. Adam D J Int Med Res; 2002; 30 Suppl 1():10A-19A. PubMed ID: 11921490 [TBL] [Abstract][Full Text] [Related]
2. Use of ampicillin/sulbactam and sultamicillin in pediatric infections: a re-evaluation. Dajani A J Int Med Res; 2001; 29(4):257-69. PubMed ID: 11675898 [TBL] [Abstract][Full Text] [Related]
3. Beta-lactam resistance: clinical implications for pediatric patients. Dajani AS J Int Med Res; 2002; 30 Suppl 1():2A-9A. PubMed ID: 11921492 [TBL] [Abstract][Full Text] [Related]
4. Experience with ampicillin/sulbactam in severe infections. Kanra G J Int Med Res; 2002; 30 Suppl 1():20A-30A. PubMed ID: 11921491 [TBL] [Abstract][Full Text] [Related]
5. Community-acquired lower respiratory tract infections: clinical experience with beta-lactam/beta-lactamase inhibitors. Lode H Int J Clin Pract Suppl; 2002 Mar; (125):10-17; discussion 37-9. PubMed ID: 12014852 [TBL] [Abstract][Full Text] [Related]
6. In vitro efficacy of beta-lactam/beta-lactamase inhibitor combinations against bacteria involved in mixed infections. Finegold SM Int J Antimicrob Agents; 1999 Aug; 12 Suppl 1():S9-14; discussion S26-7. PubMed ID: 10526868 [TBL] [Abstract][Full Text] [Related]
8. Beta-lactamase inhibitors from laboratory to clinic. Bush K Clin Microbiol Rev; 1988 Jan; 1(1):109-23. PubMed ID: 3060240 [TBL] [Abstract][Full Text] [Related]
9. Ampicillin-sulbactam: an update on the use of parenteral and oral forms in bacterial infections. Betrosian AP; Douzinas EE Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1099-112. PubMed ID: 19621991 [TBL] [Abstract][Full Text] [Related]
10. Role of sultamicillin and ampicillin/sulbactam in the treatment of upper and lower bacterial respiratory tract infections. Lode H Int J Antimicrob Agents; 2001 Sep; 18(3):199-209. PubMed ID: 11673031 [TBL] [Abstract][Full Text] [Related]
11. The role of beta-lactam/beta-lactamase inhibitors in the management of mixed infections. Akalin HE Int J Antimicrob Agents; 1999 Aug; 12 Suppl 1():S15-20; discussion S26-7. PubMed ID: 10526869 [TBL] [Abstract][Full Text] [Related]
12. The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection. Powell LL; Wilson SE Surg Infect (Larchmt); 2000; 1(1):57-63. PubMed ID: 12594910 [TBL] [Abstract][Full Text] [Related]
14. [Beta-lactam/beta-lactamase inhibitor combinations for oral administration]. Franciolli M Schweiz Med Wochenschr; 1991 Sep; 121(39):1399-407. PubMed ID: 1925470 [TBL] [Abstract][Full Text] [Related]
15. Trends in the development of beta-lactam antibiotics. Neu HC Scand J Infect Dis Suppl; 1984; 42():7-16. PubMed ID: 6597563 [TBL] [Abstract][Full Text] [Related]
16. Rational antibiotic therapy and the position of ampicillin/sulbactam. Lode HM Int J Antimicrob Agents; 2008 Jul; 32(1):10-28. PubMed ID: 18539004 [TBL] [Abstract][Full Text] [Related]
17. Clinical role of beta-lactam/beta-lactamase inhibitor combinations. Lee N; Yuen KY; Kumana CR Drugs; 2003; 63(14):1511-24. PubMed ID: 12834367 [TBL] [Abstract][Full Text] [Related]
18. Beta-lactamases and beta-lactamase inhibitors. Williams JD Int J Antimicrob Agents; 1999 Aug; 12 Suppl 1():S3-7; discussion S26-7. PubMed ID: 10526867 [TBL] [Abstract][Full Text] [Related]
19. Comparative in-vitro activity of cefoperazone-tazobactam and cefoperazone-sulbactam combinations against ESBL pathogens in respiratory and urinary infections. Patankar M; Sukumaran S; Chhibba A; Nayak U; Sequeira L J Assoc Physicians India; 2012 Nov; 60():22-4. PubMed ID: 23767198 [TBL] [Abstract][Full Text] [Related]